Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease
Trial details
- Registry ID
- NCT05327803
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as AN2-501971
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Epetraborole in Patients With Treatment-refractory MAC Lung DiseaseNCT05327803 | ANTX | Phase 2, Phase 3 | Terminated | 2024-12-18Actual |
| Phase 2 Study of Oral Epetraborole in Adults With Polycythemia VeraNCT07891533 | ANTX | Phase 2 | Not yet recruiting | 2029-04Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |